auto-activation and enzyme-assisted activation yielding mature enzyme [24] [25] [26] . By the use of a catalytically-inactive D231N cath-D expressed in a cath-D-deficient cell line [9] , we have recently shown that the mechanism of cath-D maturation was independent of its catalytic function and so implicate a fully-assisted processing similarly to that of pro-renin [LaurentMatha et al. -submitted] .
Cath-D is synthesized on the rough endoplasmic reticulum (RER) as a pre-pro-enzyme that undergoes several proteolytic cleavages during biosynthesis to produce the mature form [24, 27, 28] . Following the initial co-translational removal of the signal peptide to yield procath-D, sugars are attached at two N-linked glycosylation sites and the pro-enzyme is transported to Golgi stacks. The 52 kDa pro-cath-D then binds to mannose-6-phosphate (M6P) receptors and is targeted to lysosomes [29, 30] yielding an active intermediate 48 kDa single-chain molecule. This main proteolytic activation event most likely depends on the action of cysteine lysosomal and/or aspartic proteases [31] [32] [33] . Human cath-D catalytic sites include two critical aspartic residues (amino acid 33 and 231) located on the 14 kDa and 34 kDa chains, respectively [18] . Depending on the cell type, cath-D may also be targeted to lysosomes in a M6P-independent manner [33, 34] . The intermediate 48 kDa single-chain species is then cleaved in lysosomes into a mature two-chain enzyme consisting of a light (14 kDa) amino-terminal domain and a heavy (34 kDa) carboxyl-terminal domain. It is proposed that this proteolytic cleavage is accomplished by cysteine proteases in dense lysosomes, since processing can be partially inhibited by leupeptin [35] .
Recently, we have highlighted a requirement for both cath-B and cath-L, two lysosomal cysteine proteases widely implicated in carcinogenesis [36] , for the processing of intermediate 48 Accompanying the conversion to the two-chain species, 7 amino acid residues between light and heavy chains are removed [39] . Furthermore, several more amino acids are also removed from the carboxyl terminus of heavy chains [40] .
Pro-cath-D over-expressed by cancer cells is also secreted in excess and can be endocytosed by both cancer cells and by fibroblasts via M6P-receptors and other as yet unknown receptor(s) [9, 41] . The RAP binding chain of the LDL receptor-related protein has been excluded as being an alternative receptor for cath-D endocytosis [42] .
Endocytosed pro-cath-D undergoes maturation successively into 48kDa intermediate and 34 + 14 kDa mature forms [41, 43] . Concerning the mechanisms of cath-D maturation following its endocytosis are concerned, nothing has so far been described [44] . We have shown that the processing of endocytosed pro-cath-D was also independent of its catalytic function and requires the cysteine proteases cath-B and cath-L, similarly to cellular cath-D originating from the RER [Laurent-Matha et al.
In addition, secreted pro-cath-D, like pepsinogen, is capable of acid-dependent autoactivation in vitro [45] , resulting in a catalytically active pseudo-cath-D, an enzyme species that retains 18 residues (27-44) of the pro-segment.
Over-expression of cath-D in breast cancer cells.
Studies in estrogen receptor positive breast cancer cell lines revealed that this housekeeping enzyme is highly regulated by estrogens and certain growth factors (i.e. IGF1, EGF) [46, 47] . The mechanism of this over-expression does not seem to involve gene amplification or major chromosomal rearrangements [48] . In ER-positive breast cancer cell lines, both estrogen and growth factors stimulate cath-D protein and mRNA accumulation levels [49, 50] . As far as other steroid responsive genes are concerned, the regulation of cath-D mRNA accumulation by estrogen is mainly due to increased initiation of transcription [47] . Estrogen responsive elements have been defined in the proximal promoter region of the gene and in conjunction with other regulatory sequences (SP1, AP1) they may be responsible for the stimulation of cath-D gene expression [51] .
5. Cath-D as a prognostic factor in breast cancer.
Different approaches, such as immuno-histochemistry, in situ hybridization, cytosolic immunoassay and Northern and Western blot analyses,s have indicated that in most breast cancer tumors, cath-D is over-expressed from 2-to 50-fold compared to its concentration in other cell types such as fibroblasts or normal mammary glands [52] . Several independent clinical studies have shown that the cath-D level in primary breast cancer cytosol is an independent prognostic parameter correlated with the incidence of clinical metastasis and shorter survival times [53, 54. A meta-analysis of studies on node negative breast cancer [55] , as well as a complete study on 2810 patients in Rotterdam [56] have confirmed the value of high concentrations of cath-D as a marker of aggressiveness.
The major cath-D producing cells appear to be cancer cells and stromal macrophages [57] . Cath-D production by fibroblasts appears variable according to various publications. Certain studies have indicated that cath-D production is low relative to cancer cells as shown by immunochemistry [57] and in situ hybridization with antisense RNA [58] . Other studies have indicated a prognostic role for cath-D over-expression by reactive stromal cells [59] [60] [61] [62] . Pro-cath-D is also increased in the plasma of patients with metastatic breast cancer [63, 64] , indicating that part of the pro-cath-D secreted by tumors can be released into the circulation. [65, 66] . In this rat tumor model, the cath-D mechanism responsible for metastasis stimulation seemed to have a positive effect on cell proliferation, favouring the growth of micrometastases, rather than increasing the invasive potential [65] [66] [67] [68] [69] . Using an RNA antisense strategy we showed that cath-D was a rate limiting factor in the outgrowth, tumorigenicity and lung colonization of MDA-MB-231 breast cancer cells [70] .
Cath-D as a mitogen for cancer cells.
Several reports have indicated that cath-D stimulates cancer cell proliferation. Vignon and colleagues first showed that purified pro-cath-D from MCF-7 breast cancer cells stimulated MCF-7 cell growth [43] . Moreover, 3Y1-Ad12 rat cancer cells transfected with human cath-D cDNA grew more rapidly both at low or high cell densities in vitro and showed an increased experimental metastatic potential in vivo [65] [66] [67] . In addition, Vetvicka and colleagues reported that pro-cath-D was mitogenic for breast and prostate cancer cells [71] [72] [73] .
Different mechanisms have been proposed as responsible for the mitogenicity of cath-D. On the one hand, it has been proposed that its action as a ligand might involve either an interaction with the M6P moieties of cath-D with the M6P/IGF-2 receptor or even an interaction of a part of its pro-fragment (amino acids 27 to 44) with an unknown cell surface receptor [71, [74] [75] [76] . Alternatively, its catalytic activity in activating growth factors has been implicated [77, 78] or to prevent secretion of growth inhibitors [67] . The question remains as to whether secreted pro-cath-D could be activated extra-cellularly in a sufficiently acidic milieu. Indeed, the extracellular pH in tumors is generally more acidic that in corresponding normal tissues [79] . Recently we demonstrated that a mutated D231N cath-D devoid of proteolytic activity was still mitogenic both in vitro in three dimensional (3D) matrices and in vivo in athymic nude mice [11, 68, 69] . These results therefore suggest that pro-cath-D may be acting as an extra-cellular binding protein and not as a protease by triggering either directly or indirectly an as yet unidentified cell surface receptor (Figure 1 ).
Role of cath-D in angiogenesis.
It is well established that tumor growth is dependent on angiogenesis [80] . Immunohistochemical studies have indicated that cath-D, independently of its proteolytic activity, stimulates not only cancer cell proliferation, but also tumor angiogenesis [69] . In this same study, we have demonstrated that human cath-D over-expressed by cancer cells significantly stimulated tumor angiogenesis in tumor xenografts in athymic mice.
Contrary to the case with other proteolytic enzymes, degradation of the extracellular matrix (ECM) did not seem to be implicated as a mechanism for cath-D [81] , since catalytically-inactive D231N cath-D was as potent as wild-type cath-D in inducing angiogenesis [69] .
The potential role of cath-D in angiogenesis has not yet been fully defined. An initial study suggested that cath-D might stimulate angiogenesis by releasing ECM-bound bFGF in breast cancer cells [77] . Moreover, a clinical study on 102 invasive breast carcinomas revealed a statistically significant association between cath-D expression and higher vessel counts [82] . However, it has also been reported that pro-cath-D secreted by prostate carcinoma cells might be responsible for the generation of angiostatin, which is a specific inhibitor of angiogenesis in vivo [83] . More recently, cath-D was also reported to cleave human prolactin, generating multiple 16K-like N-terminal prolactin fragments with antiangiogenic properties [84] .
On the basis of our observations [69] , we speculate that cath-D may stimulate endothelial cell growth via a paracrine loop, acting as a protein ligand, and either directly or indirectly triggering an as yet unidentified cell surface receptor -that could be present on both cancer cells, as previously suggested [68] and on endothelial cells (Figure 1 ).
Paracrine action of cath-D on fibroblasts. 6.4.1 Stromal cells play a determinant role in cancer pathogenesis.
Interaction between stromal cells and epithelial cells appears to be important for both normal development and neoplasis [85] . The identification of genes that are selectively expressed in the stroma of malignant lesions has provided new insight into the molecular basis of stromal-epithelial interactions. Stromally expressed genes include growth factors, proteases and extracellular matrix proteins, all biological activities with potential roles in malignant progression [86] . Stromal and tumor cells interchange numerous growth factors and proteases to activate the adjacent extracellular matrix and, in turn, induce the selection and expansion of neoplastic cells [86] . The fibroblast is a major cell type of the stromal compartment and, as such, is intimately involved in orchestrating the stromal part of the dialogue in tissue homeostasis [87] . The modification of fibroblasts in the stroma immediately adjacent to transformed epithelial cells has been documented in several tumor systems [88] [89] [90] .
Stroma and cancer cells can interchange proteases.
There is a lot of evidence that extracellular matrix, depending on its context, can actively regulate cellular processes such as growth, death, adhesion, migration, invasion, gene expression and differentiation [91] [92] [93] . Each cell type displays surface receptors appropriate for its tissue environment and interaction of these receptors with extracellular matrix components influence cell shape, behaviour and the response to soluble molecules including cytokines and growth factors [94] . During the transition from normal tissue to in situ and invasive carcinoma, the micro-environment of the local host stroma is an active player. In fact, stroma and tumor cells can interchange growth factors and also proteases, for example, matrix metalloproteases (MMPs) and urokinase plasminogen activator (uPA), to activate the adjacent extracellular matrix and, in turn, induce the selection and expansion of neoplastic cells [86] . Increased stromal growth accounts for most of the increase in breast volume in the post-puberbal years and also occurs in breast cancer.
Cath-D promotes fibroblast outgrowth in 3D matrices.
Cath-D, described as being localized to the surface of breast fibroblasts [95] , might well be a mitogen that induces stromal proliferation. Indeed, we recently demonstrated a requirement of cath-D for fibroblast invasive growth using a 3D co-culture assay with cancer cells either secreting or not secreting pro-cath-D [9] . Ectopic expression of cath-D in cath-Ddeficient fibroblasts stimulated 3D outgrowth and was associated with a significant increase in fibroblast proliferation, survival, motility and invasive capacity, as well as by activation of the ras-MAP kinase pathway [9] . Interestingly, all these stimulatory effects on fibroblasts were independent of cath-D proteolytic activity [9] .
The question remains, however, as to how cath-D induces such a major change in fibroblast phenotype. Since fibroblasts can become activated by either catalytically-active orinactive cath-D or indeed by the secreted pro-cath-D precursor, its proteolytic activity is clearly not directly involved in the stimulatory effect [9] . At present, the only receptor known to interact with the secreted pro-cath-D is M6P/IGF2 receptor, which has a well defined function in the transport of various ligands via the endosomal pathway [44] . However, the ability of this receptor to stimulate cellular responses via signaling pathways remains controversial although a recent study indicates that it may transduce IGF2 mitogenic activity via the MAP kinase pathway [96] .
Another possibility is that secreted pro-cath-D binds to an as yet unidentified cell surface receptor coupled to the MAP kinase transduction pathway. Indeed it has been proposed that such a receptor exists at the cell surface of cancer and endothelial cells to mediate cath-D mitogenic activity [41, 68, 69, 71] .
We therefore propose that cath-D may favor tumor progression not only by affecting the epithelial compartment, but also by promoting fibroblast outgrowth via a paracrine loop (Figure 1 ). Under these circumstances, cath-D over-expressed and hyper-secreted by cancer cells may be captured in vivo by stromal cells, may promote proliferation and survival, may stimulate motility and invasion of fibroblasts and consequently may enhance tumor-host homeostasis.
Cath-D hyper-secreted by breast cancer cells is captured by fibroblasts.
In addition to the degradation of the extracellular matrices, an increased stromal growth has also been described as occurring in tumors [90] . Tumor fibroblasts confer both morphogenic and mitogenic induction of epithelial cells and further enhancement of growth and progression requires active angiogenesis [90] . Therefore the factors required for the normal behaviour of fibroblasts are crucial. If these factors are over-expressed by cancer cells and can be captured by fibroblasts, then they might optimize the behaviour of fibroblasts thereby enhancing tumor development and progression.
Pro-cath-D secreted by breast cancer cells can be captured by fibroblasts [9, 41, 97] . According to these reports and to our previous report indicating a stimulatory effect of cath-D on tumor angiogenesis [69] , cath-D over-expressed and hyper-secreted by breast cancer cells might be a mitogen that induces stromal proliferation in tumors. Moreover, stromal fibroblasts contribute extensively to the serine protease and MMP activities in tumors [88, 98, 99] . We were unable to detect any significant change in the mRNA expression of uPA, PAI1, MMP2, MMP9, MMP14, TIMP-1 and TIMP-2 in cath-D transfected fibroblasts [9] . However, cath-D may, by stimulating the growth of fibroblasts, indirectly increase the level of the other proteases implicated in the degradation of the extracellular matrix.
Conversely, the ability of extracellular matrix components to mediate expression of proteases has not yet been fully examined. Indeed, it has been shown that interaction of human breast fibroblasts with collagen I increased the secretion of pro-cath-B, but not that of pro-cath-D [95] .
Action of secreted cath-D as a binding protein.
Initially, it was believed that the major role of proteases in metastasis was to facilitate the invasion of cancer cells by digesting the extra-cellular matrix and the basement membrane components [100] . Other evidence though suggests that proteases are also key regulators of tumor growth at both the primary and metastatic sites [101] . Moreover, it is generally assumed that the mechanism of mitogenic activity of proteases is due to their proteolytic activities facilitating either growth factor release [78] , or growth inhibitor deterioration [67] , or proteolytic activation of a mitogenic receptor, as shown for the thrombin receptor [102] . Like proteases acting at a neutral pH, such as the plasminogen activator and the matrix metalloproteases, the precursors of lysosomal proteases (e.g. pro-cath-B, D, and L) are also over-expressed and hyper-secreted by carcinoma cells [8, 103, 104] .
Hyper-secreted cath-D might act either as a protease after its extracellular activation at an acidic pH or as a binding protein and its action could take place extracellularly as suggested by the high hyper-secretion of this pro-enzyme or intracellularly following its endocytosis via membrane receptors [11] . Degradation of the basement membrane after secretion and extracellular activation is unlikely to be the major mechanism for cath-D action, in contrast to neutral proteases, since cath-D activation requires an acidic pH which is found intra-cellularly in endosomes, lysosomes or phagosomes. At present, it is difficult to exclude any of these mechanisms, but our recent results strongly favour the hypothesis of cath-D acting as a secreted binding protein. Indeed, we reported that D231N cath-D mutated in its catalytic site and hence devoid of proteolytic activity, was still mitogenic for cancer, endothelial and fibroblastic cells, possibly by interacting with an unknown membrane receptor [9, 68, 69] (Figure 1) . Moreover, according to the Fusek and Vetvicka model, procath-D may act as a ligand by triggering a trans-membrane receptor via its pro-peptide [71, [74] [75] [76] . Another mechanism by which cath-D could be mitogenic on cancer cells, without activation at neutral pH, is by competing with IGFII on the M6P/IGFII receptor resulting in an activation of the IGFI receptor [105] .
These mechanisms though are not mutually exclusive and, according to the conditions observed locally in vivo in the tumor (particularly pH and oxygenation), the importance of one mechanism or the other could vary. Cath-D, contrary to other proteases, therefore seems to be more of a mitogen than a protease, allowing cancer cells to cross the basement membrane and invade connective tissue or enter the blood stream.
Complex role of cath-D in apoptosis.

Physiologic and pathologic role of cath-D in apoptosis.
The function of cath-D in apoptosis is not yet fully understood and needs further investigation. Cath-D can either prevent apoptosis, as described under physiological conditions with cath-D knock-out mice experiments [4] [5] [6] [7] , or can promote apoptosis induced by cytotoxic agents [106] [107] [108] [109] [110] [111] [112] [113] [114] . This duality in the role of cath-D in apoptosis is also highlighted by our apparently conflicting results obtained with transfected 3Y1-Ad12 cell lines. Indeed, we previously published that over-expressed cath-D was preventing tumor apoptosis in a manner dependent on its catalytic function in cath-D transfected 3Y1-Ad12 xenografts [69] . Intriguingly, our recent study performed with the same cell lines, but this time treated with chemotherapeutic agents indicates a stimulation of apoptosis independently of cath-D catalytic activity [Beaujouin et al. -submitted] . It seems, therefore, that depending on the environmental conditions, cath-D may either inhibit or promote apoptosis via different mechanisms. This raises the interesting possibility that this protease is implicated as being involved in more than one apoptotic pathway.
Cath-D is a key mediator of induced-apoptosis in cancer cells.
Cath-D has been discovered as a key mediator of apoptosis induced by many apoptotic agents [10] , such as IFN-gamma, FAS/APO, TNF-alpha [106] , oxidative stress [108] [109] [110] [111] [112] , adriamycin and etoposide [107, 114] , cisplatin and 5-fluorouracil [114] as well as staurosporine [113] . The role of cath-D in apoptosis has been linked to the lysosomal release of mature 34 kDa cath-D into the cytosol, leading in turn to the mitochondrial release of cytochrome c (cyt c) into the cytosol [108-111, 113, 115] , activation of pro-caspases -9 and -3 [109, 113, 115, 116] , in vitro cleavage of Bid at pH 6.2 [116] , or Bax activation independently of Bid cleavage [117] (Figure 2) . Numerous studies have shown that pepstatin A, an aspartic protease inhibitor, could partially delay apoptosis induced by IFN-gamma and FAS/APO [106] , staurosporine [113, 117, 118] , TNF-alpha [106, 116, 119] , serum deprivation [120] , oxidative stress [109] [110] [111] [112] or even when pepstatin A was co-micro-injected with cath-D [115] . These authors have therefore concluded that cath-D plays a key role in apoptosis mediated via its catalytic activity.
However, cath-D is one of the lysosomal enzymes which require a more acidic pH to be proteolytically active relative to the cysteine lysosomal enzymes such as cath-B and -L. Acidification of the cytosol down to pH values of about 6.7-7 is a well-documented phenomenon in apoptosis [121, 122] . However, cath-D can cleave its substrates up to a pH of 6.2 in vitro, but not above that level [123] . Hence, it is predictable that the proteolytic activity of cytosolic cath-D would be drastically impaired under adverse pH conditions, unfavourable for its catalytic function. It therefore remains open to question as to whether cath-D might be able to cleave cytosolic substrate(s) implicated in the apoptotic cascade. In accordance with this proposition, it has recently been shown that pepstatin A did not prevent the death of cells treated by either etoposide, doxorubicin, TNF-alpha or anti-CD95 [114, 119, 124] . Furthermore, pepstatin A did not suppress Bid cleavage or pro-caspases-9 and -3 activation by photodynamic therapy in murine hepatoma cells [125] . Finally, a deficiency in cath-D activity did not alter cell death induction in CONCL fibroblasts [124] .
Conclusion.
Cath-D is not only a mitogen for cancer cells but appears to be also a crucial paracrine factor for endothelial and fibroblastic cells. Its action in cancer seems to implicate its extracellular interaction with a cell surface membrane receptor. This receptor has not yet been identified, but it is clearly of considerable potential interest to clarify the mechanisms involved and to consider their medical applications. Cath-D evidently plays a dual role in apoptosis. In such physiological and pathological conditions as cancer this protease prevents apoptosis, whereas it is also established as a key positive mediator of induced-apoptosis. Upon induction of apoptosis, lysosomal mature 34 kDa cath-D is rapidly released from the lysosomes into the cytosol, leading in turn to the mitochondrial release of cytochrome c (cyt c) into the cytosol and caspase-9 activation after binding to Apaf-1 (apoptosis proteaseactivating factor) and caspase-3 activation [1] . The mechanism(s) of how cath-D mediates apoptosis remain(s) unknown. A possible mode of cath-D action may be the truncation of Bid into tBid in the cytosol. tBid may induce formation of the active Bax conformation in the cytosol by direct tBid/bax interaction, allowing Bax insertion in the outer mitochondrial membrane and subsequent release of cyt c [1] . Alternatively, cath-D may also be required, via Bid-independent pathways, for the Bax-mediated release of AIF (Apoptosis Inducing Factor) from mitochondria into the cytoplasm and the nucleus, which in turn causes chromatin remodelling and early commitment to caspase-independent apoptosis [2] . 
